human pluripotent embryonic stem cell-derived keratinocyte epidermis (INSERM)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namehuman pluripotent embryonic stem cell-derived keratinocyte epidermis (INSERM)
Drug Alias NamehESC-derived keratinocyte epidermis (INSERM)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionEpidermal growth factor receptor erbB1 agonistsKeratinocytes stimulants
TargetsKeratinocytesEpidermal growth factor receptor erbB1
Therapy Area/IndicationsBurnsWounds and Injuries
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesInstitut National De La Sante Et De La Recherche Medicale
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstitut National De La Sante Et De La Recherche MedicaleInserm Transfert
Active IndicationsN/A
Inactive IndicationsBurnsWounds and Injuries

Other Information

ATC CodeN/A
Related LinksN/A